HealthlineTestosterone Prescriptions for Women Surge Amid Pharmacy Access Barriers

📋 Regulatory Action / Label Change

Testosterone prescriptions for women reportedly increased substantially between 2023 and 2026, reflecting growing interest in hormonal symptom management during menopause. At the same time, the lack of FDA-approved female-specific testosterone formulations has created practical prescribing and dispensing challenges, while regulators continue to seek stronger evidence supporting broader use beyond sexual dysfunction.

Professional Impact

• Current guideline support remains focused on hypoactive sexual desire disorder (HSDD) in postmenopausal women rather than generalized menopause symptom management.
• No FDA-approved testosterone products for women currently exist, requiring off-label use of male formulations at reduced doses.
• Pharmacy dispensing challenges may emerge when prescribed doses require product division, customization, or non-standard administration approaches.
• Evidence supporting testosterone for fatigue, mood, muscle strength, bone density, or general well-being remains limited and inconsistent.
• Maintaining testosterone levels within the physiologic premenopausal female range remains an important safety consideration when therapy is used.
• Ongoing clinical trials and FDA interest may eventually clarify efficacy, safety, and product development pathways for female-specific formulations.

Action Items

• Review current Menopause Society guidance before considering testosterone therapy for menopause-related symptoms.
• Document the indication and counseling discussion when prescribing off-label testosterone therapy.
• Monitor testosterone dosing and laboratory targets to avoid supraphysiologic exposure.
• Evaluate pharmacy dispensing limitations that could affect patient access or adherence.
• Track emerging FDA developments and ongoing clinical trial results regarding female-specific testosterone products.